On July 17, 2001, Talwar, Naresh; Sen, Himadri; Staniforth, John N. published a patent.Related Products of 86393-32-0 The title of the patent was Orally administered controlled drug delivery system providing temporal and spatial control. And the patent contained the following:
A pharmaceutical composition in the form of tablets or capsules provides a combination of temporal and spatial control of drug delivery to a patient for effective therapeutic results. The pharmaceutical composition comprises a drug, a gas generating component, a swelling agent, a viscolyzing agent, and optionally a gel forming polymer. The swelling agent belongs to a class of compounds known as super-disintegrants (e.g., cross-linked polyvinylpyrrolidone or sodium CM-cellulose). The viscolyzing agent initially and the gel forming polymer thereafter form a hydrated gel matrix which entraps the gas, causing the tablet or capsule to be retained in the stomach or upper part of the small intestine (spatial control). At the same time, the hydrated gel matrix creates a tortuous diffusion path for the drug, resulting in sustained release of the drug (temporal control). A preferred once daily ciprofloxacin formulation comprises 69.9 ciprofloxacin base, 0.34 sodium alginate, 1.03 xanthan gum, 13.7 sodium bicarbonate, 12.1 cross-linked polyvinylpyrrolidone, and optionally other pharmaceutical excipients, the formulation being in the form of a coated or uncoated tablet or capsule. A tablet contained ranitidine hydrochloride (I) 300.00, xanthan gum (Keltrol TF) 20.00, sodium alginate (Keltone LVCR) 20.00, cross-linked CM-cellulose 50.00, sodium bicarbonate 50.00, magnesium stearate 5.00, and talc 5.00%. The % cumulative release of I from the tablets was 84.37% after 8 h. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Related Products of 86393-32-0
The Article related to oral controlled drug delivery system, ranitidine controlled release tablet, Pharmaceuticals: Formulation and Compounding and other aspects.Related Products of 86393-32-0
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics